Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gynecologic Oncology

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2016.09.014PMID 27692668PMCID PMC5624326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epithelial ovarian cancer

  2018cited by this paper
• OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

  2018cited by this paper
• Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

  2016cited by this paper
• A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study

  2016cited by this paper
• Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

  2016cited by this paper
• Personalized surgical therapy for advanced ovarian cancer: R0 resection after neoadjuvant chemotherapy is associated with decreased event-free survival compared with primary cytoreductive surgery

  2016cited by this paper
• Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

  2016cited by this paper
• OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).

  2016cited by this paper
• Predicting outcomes at primary debulking surgery for advanced epithelial ovarian, fallopian tube, and peritoneal cancer

  2015cited by this paper
• Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

  2015cited by this paper
• The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

  2014cited by this paper
• Does Modality of Adjuvant Chemotherapy After Interval Surgical Debulking Matter in Epithelial Ovarian Cancer?: An Exploratory Analysis

  2014cited by this paper
• Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

  2013cited by this paper
• Optimal (≤1 cm) but visible residual disease: is extensive debulking warranted?

  2013cited by this paper
• Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

  2012cited by this paper
• Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921.

  2011cited by this paper
• Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.

  2011cited by this paper
• Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

  2011cited by this paper
• Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.

  2011cited by this paper
• Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?

  2011cited by this paper
• 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

  2011cited by this paper
• Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization.

  2011cited by this paper
• Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

  2010cited by this paper
• Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia

  2009cited by this paper
• Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.

  2009cited by this paper
• Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

  2005cited by this paper
• Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

  2005cited by this paper
• Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

  2001cited by this paper
• Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

  1996cited by this paper

• LncRNA LINC00261 associates with chemoresistance and clinical prognosis in patients with epithelial ovarian cancer

  2024cites this paper
• Циторедуктивные операции в комбинированном лечении диссеминированного рака яичников

  2023cites this paper
• Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies.

  2023cites this paper
• Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis

  2023cites this paper
• Long term survival of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in advanced epithelial ovarian cancer

  2021cites this paper
• Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence

  2020cites this paper
• Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

  2020cites this paper
• Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties

  2020cites this paper
• Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer

  2020cites this paper
• A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.

  2019cites this paper
• Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin.

  2018cites this paper
• [Surgical treatment of peritoneal metastases from gynecological primary tumors].

  2018cites this paper
• Chirurgische Therapie bei peritonealen Metastasen gynäkologischer Primärtumoren

  2018cites this paper
• Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer

  2018cites this paper